Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
about
Trial Watch: Adoptive cell transfer for oncological indicationsHIV-1 functional cure: will the dream come true?Cellular immunotherapy for pediatric solid tumorsT cell engineering as therapy for cancer and HIV: our synthetic futureEngineering T Cells to Functionally Cure HIV-1 InfectionDesigning chimeric antigen receptors to effectively and safely target tumorsAn Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersChimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.Progress and prospects of gene therapy clinical trials for the muscular dystrophies.Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activityCurrent advances in T-cell-based cancer immunotherapyRegional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor ActivityInducible T-cell receptor expression in precursor T cells for leukemia control.Fully human CD19-specific chimeric antigen receptors for T-cell therapy.Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.Chimeric Antigen Receptor T Cell Therapy in Hematology.IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cellsRole of memory T cell subsets for adoptive immunotherapy.Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasiaImmunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research.Engineering T cells for cancer: our synthetic future.Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis.Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014).Overcoming tumor-mediated immunosuppression.Overcoming the toxicity hurdles of genetically targeted T cells.Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.CAR T-cell therapy: toxicity and the relevance of preclinical models.Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.Immunological landscape and immunotherapy of hepatocellular carcinoma.Bioengineering solutions for manufacturing challenges in CAR T cells.Manufacturing Cell Therapies Using Engineered Biomaterials.The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.
P2860
Q26785545-4CA96E17-D4B7-4395-8E72-18379F34406BQ26865803-B5B80828-A0F3-480A-A5C4-25DDC7732FAEQ27014912-2CAEC3E5-D597-4E7D-B444-749C915FB46FQ28082253-AB82094D-C5B2-465B-8476-28F6A6F2D986Q28086801-D4F88BAA-5CDB-4BF2-A7F9-FED91C625DC4Q28088526-F4A5E194-0E04-4867-9E2F-983B35318FACQ28551080-25FB563A-6D81-4067-A19D-AF61D3F9EA03Q34044910-96EAA6F1-8533-49C8-AFF4-BD8BA6FDE5A0Q34177641-F4569DC8-12B4-4A35-9CB9-D659C11E80A3Q34497471-38124432-6188-4E41-AE12-EFD77288CE9BQ34765959-7F57174D-B225-4940-B5B3-3C8399FACF26Q35215158-D386123A-930C-4D6B-9E5C-68EF96866E68Q35216278-C559EA62-5E06-46D9-B76A-1F8F9587D8F4Q35745453-A34D9EAC-BD13-4A8B-B414-08FE9C5CE103Q36166038-3CA35EC6-747B-44BA-91EF-A3D2E70E30B9Q36281920-DDCBFEDB-4300-4F0D-8C1A-9C98C2E166CFQ36430680-F6CE4A2D-505A-45ED-B458-7353997EA26AQ36721440-6497C77A-9F9D-404C-98AF-72270DA51F15Q36722700-F4524B9A-F063-4AFB-B234-9F10EEE7CAB4Q36727794-069E7E73-BCE2-43B9-B180-34B435B98CCEQ37263366-599E6D0F-0D8B-435F-92BB-28F1FF786735Q37395790-B83FDED6-E0F1-460A-9029-714BD2DBDC90Q37417622-073CC5BD-2254-4B9E-808B-5C1D5C567A14Q37515502-2B8E5C7E-5A7C-4BB4-83F3-92FF28639EFAQ37696129-21FC152B-C2FE-42AC-9678-BD2A9143478EQ38197075-EA18F90A-E04A-4608-838E-398B5352AD60Q38199350-F6706CC9-5B72-472D-A4DF-92D9B62F87D2Q38229212-A19CA4F3-957B-499B-805B-8048319B9782Q38235439-B97B9F44-E0FB-4F88-AB7D-D13311DD0EEBQ38262255-355CE144-576B-4677-B27D-F071785B1987Q38285543-5373186B-5B40-45AB-A51C-DA4D20C86167Q38399051-FC7A44FD-9B6A-4EDC-B6E5-C202B79530A3Q38435415-187EB303-ACA4-4D9B-9A40-F6FDBB4A5400Q38445486-BF92ABD9-642D-4E6C-A68F-75016279BFB6Q38525018-2A1205A2-D927-49AB-813C-B97C02B0DF59Q38538645-279A6311-C3DD-4B15-8546-EEA29EC2C24BQ38611895-A5C99D47-1D6F-4FA9-97CF-C29DA02FA0EFQ38637370-EE90C615-6D36-47F0-B84F-2F165B9D3623Q38657159-22829ED7-689A-4799-AB9A-CEB28132565EQ38764944-C52BE55C-7A0C-4168-BE16-5CE9B17E6008
P2860
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Design and implementation of a ...... gen receptor-modified T cells.
@en
type
label
Design and implementation of a ...... gen receptor-modified T cells.
@en
prefLabel
Design and implementation of a ...... gen receptor-modified T cells.
@en
P2860
P356
P1476
Design and implementation of a ...... gen receptor-modified T cells.
@en
P2093
Michael C Jensen
Stanley R Riddell
P2860
P304
P356
10.1111/IMR.12139
P577
2014-01-01T00:00:00Z